PROTAC BRD4 Degrader-3 is primarily used in biomedical research to target and degrade the BRD4 protein, which plays a significant role in regulating gene expression and is implicated in various cancers. Its application is crucial in studying the mechanisms of protein degradation and developing potential therapeutic strategies for diseases where BRD4 is overexpressed or dysregulated, such as certain types of leukemia, lymphoma, and solid tumors. Researchers utilize this compound to investigate the efficacy of targeted protein degradation as a novel approach to cancer treatment, offering a promising alternative to traditional inhibitors. Additionally, it aids in understanding the broader implications of BRD4 in cellular processes, including its role in inflammation and epigenetic regulation. This makes it a valuable tool in both preclinical studies and drug discovery efforts.